Dossier assessment

Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-102
Last updated

Report documents

  1. Extract of dossier assessment

    Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 605 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-102_en
  2. Dossier assessment

    Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-102

Dossier assessment

Indication:

Adult patients with completely resected non-small cell lung cancer at high risk of recurrence after platinum-based chemotherapy whose tumours express PD-L1 in ≥ 50% of the tumour cells and who do not have EGFR mutations or ALK-positive NSCLC; adjuvant treatment

Result of dossier assessment:

Hint of minor added benefit

Project details

Project no.
A24-102
Commission
Commission awarded on 27.09.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-102_en

Connected Projects

  1. Dossier assessment

    Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-97
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-67
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-69
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-97
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-86
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-84
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-83
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-81
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-52
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-51
    Last updated

    Status: Commission completed

  11. Dossier assessment

    Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-50
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form